Immunotherapy advances for glioblastoma

Survival for patients with glioblastoma, the most common high-grade primary CNS tumor, remains poor despite multiple therapeutic interventions including intensifying cytotoxic therapy, targeting dysregulated cell signaling pathways, and blocking angiogenesis. Exciting, durable clinical benefits have...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Reardon, David A., Freeman, Gordon, Wu, Catherine, Chiocca, E. Antonio, Wucherpfennig, Kai W., Wen, Patrick Y., Fritsch, Edward F., Curry, William T., Sampson, John H., Dranoff, Glenn
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Reviews
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201077/
https://ncbi.nlm.nih.gov/pubmed/25190673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou212
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires